Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia

Bibliography

• DSM-IV: Primary insomnia. In: Diagnostic and Statistical Manual of Mental Disorders. 4th edition. American Psychiatric Association. Available from: http://dsm.psychiatryonline.org/data/PDFS/dsm-iv.pdf accessed 2012
   Google Scholar
• ICD-10: Nonorganic insomnia. In: International Classification of Diseases. 10th edition. World health Organization (WHO); Available from:http://apps.who.int/classifications/icd10/browse/2010/en accessed 2012
   Google Scholar
• Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007;3:S7-10
   PubMed Web of Science ®Google Scholar
• Walsh JK, Coulouvrat C, Hajak G, Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS) running heading: nighttime insomnia symptoms in the AIS. Sleep 2011;34:997-1011
   PubMed Web of Science ®Google Scholar
• Ford DE, Kamerov D. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989;262:1479-84
   PubMed Web of Science ®Google Scholar
• Pearson NJ, Johnson LL, Nahin RL. Insomnia, trouble sleeping, and complementary and alternative medicine: analysis of the 2002 National Health Interview Survey data. Arch Intern Med 2006;166:1775-82
   PubMed Web of Science ®Google Scholar
• Taylor DJ, Mallory LJ, Lichstein KL, Comorbidity of chronic insomnia with medical problems. Sleep 2007;30:213-18
   PubMed Web of Science ®Google Scholar
• Roth T. Comorbid insomnia: current directions and future challenges. Am J Manag Care 2009;15:S6-13
   PubMed Web of Science ®Google Scholar
• Hatoum HT, Kong SX, Kania CM, Insomnia, health-related quality of life and healthcare resource consumption. A study of managed-care organisation enrollees. Pharmacoeconomics 1998;14:629-37
   PubMed Web of Science ®Google Scholar
• Hajak G. Epidemiology of severe insomnia and its consequences in Germany. Eur Arch Psychiatry Clin Neurosci 2001;251:49-56
   PubMed Web of Science ®Google Scholar
• Roth T, Hajak G, Ustun T. Consensus for the pharmacological managment of insomnia in the new millennium. Int J Clin Pract 2001;55:1-10
   Web of Science ®Google Scholar
• Leger D, Guilleminault C, Bader G, Medical and socio-professional impact of insomnia. Sleep 2002;25:625-9
   PubMed Web of Science ®Google Scholar
• Novak M, Mucsi I, Shapiro CM, Increased utilization of health services by insomniacs - an epidemiological perspective. J Psychosom Res 2004;56:527-36
   PubMed Web of Science ®Google Scholar
• Fullerton DS. The economic impact of insomnia in managed care: a clearer picture emerges. Am J Manag Care 2006;12:S246-52
   PubMed Web of Science ®Google Scholar
• Morgan K, Healey DW, Healey PJ. Factors influencing persistent subjective insomnia in old age: a follow-up study of good and poor sleepers aged 65 to 74. Age Ageing 1989;18:117-22
   PubMed Web of Science ®Google Scholar
• Bliwise DL, King AC, Harris RB, Haskell WL. Prevalence of self-reported poor sleep in a healthy population aged 50 – 65. Soc Sci Med 1992;34:49-55
   PubMed Web of Science ®Google Scholar
• Ohayon M. Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiatr Res 1997;31:333-46
   PubMed Web of Science ®Google Scholar
• Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: results of the 1991 national sleep foundation survey. Sleep 1999;22:S354-8
   PubMed Web of Science ®Google Scholar
• Roth T, Roehrs T. Insomnia: epidemiology, characteristics, and consequences. Clin Cornerstone 2003;5:5-15
   PubMedGoogle Scholar
• Morgan K, Dallosso H, Ebrahim S, Characteristics of subjective insomnia in the elderly living at home. Age Aging 1988;17:1-7
   PubMed Web of Science ®Google Scholar
• Buysse D, Reynolds C III, Monk T, The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatr Res 1989;28:193-213
   PubMed Web of Science ®Google Scholar
• Zeitlhofer J, Schmeiser-Rieder A, Tribl G, Sleep and quality of life in the Austrian population. Acta Neurol Scand 2000;102:249-57
   PubMed Web of Science ®Google Scholar
• Hauri PJ. Cognitive deficits in insomnia patients. Acta Neurol Belg 1997;97:113-17
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 national sleep foundation survey. I. Sleep 1999;22:S347-53
   PubMed Web of Science ®Google Scholar
• Crenshaw C. Slow-wave sleep and waking cognitive performance among older adults with and without insomnia complaints. Physiol Behav 1999;66:485-92
   PubMed Web of Science ®Google Scholar
• Leger D, Poursain B, Neubauer D, Uchiyama M. An international survey of sleeping problems in the general population. Curr Med Res Opin 2008;24:307-17
   PubMed Web of Science ®Google Scholar
• Hoevenaar-Blom MP, Spijkerman A, Kromhout D, Sleep duration and sleep quality in relation to 12-year cardiovascular disease incidence: the MORGEN Study. Sleep 2011;34:1487-92
   PubMed Web of Science ®Google Scholar
• Bansil P, Kuklina EV, Merritt RK, Yoon PW. Associations between sleep disorders, sleep duration, quality of sleep, and hypertension: results from the National Health and Nutrition Examination Survey, 2005 to 2008. J Clin Hypertens (Greenwich) 2011;13:739-43
   PubMed Web of Science ®Google Scholar
• Ohayon M, Zulley J. Correlates of global sleep dissatisfaction in the German population. Sleep 2001;24:780-7
   PubMed Web of Science ®Google Scholar
• Bastien CH, Fortier-Brochu E, Rioux I, Cognitive performance and sleep quality in the elderly suffering from chronic insomnia. Relationship between objective and subjective measures. J Psychosom Res 2003;54:39-49
   PubMed Web of Science ®Google Scholar
• Backhaus J, Junghanns K, Born J, Impaired declarative memory consolidation during sleep in patients with primary insomnia: influence of sleep architecture and nocturnal cortisol release. Biol Psychiatry 2006;60:1324-30
   PubMed Web of Science ®Google Scholar
• Hohagen F, Rink K, Kappler C, Prevalence and treatment of insomnia in general practice. Eur Arch Psychiatry Clin Neurosci 1993;242:329-36
   PubMed Web of Science ®Google Scholar
• Scharf MB, Mayleben DW, Kaffeman M, Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry 1991;52:77-83
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Primary Care Companion. J Clin Psychiatry 1999;1:114-20
   Google Scholar
• Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004;18:297-28
   PubMed Web of Science ®Google Scholar
• Vgontzas A, Kales A, Bixler EO. Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Pharmacology 1995;51:205-23
   PubMed Web of Science ®Google Scholar
• Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999;47:30-9
   PubMed Web of Science ®Google Scholar
• Szabadi E. Drugs for sleep disorders: mechanisms and therapeutic prospects. Br J Clin Pharmacol 2006;61:761-6
   PubMed Web of Science ®Google Scholar
• Glass J, Lanctot KL, Herrmann N, Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005;331:1169-76
   PubMed Web of Science ®Google Scholar
• Zimovane: summary of Product Characteristics (SPC): Zimovane, Zimovane LS. Available from: http://www.medicines.org.uk/EMC/medicine/1675/SPC/Zimovane+7.5mg+%26+Zimovane+LS+3.75mg+film-coated+tablets/ Accessed 2012
   Google Scholar
• Stilnoct: Summary of Product Characteristics (SPC): Stilnoct 5 mg, Stilnoct 10 mg. Available from: http://www.medicines.org.uk/EMC/medicine/6992/SPC/Stilnoct+5mg%2c+Stilnoct+10mg/ Accessed 2012
   Google Scholar
• Zaleplon: European Public Assessment Reports for Sonata (Zaleplon). Available from: http://www.mhra.gov.uk/Publications/Safetyguidance/CurrentProblemsinPharmacovigilance/CON2024486accese Accessed 2012
   Google Scholar
• MHRA: Committee on Safety of Medicines: Current Problems in Pharmacovigilance. 1998;21:1–4 Available from: http://www.mhragov.uk/Publications/Safetyguidance/CurrentProblemsinPharmacovigilance/CON2024486 Accessed 2012
   Google Scholar
• Busto UE, Sellers EM. Anxiolytics and sedative/hypnotics dependence. Br J Addict 1991;86:1647-52
   PubMedGoogle Scholar
• Siriwardena AN, Qureshi MZ, Dyas JV, Magic bullets for insomnia? Patients' use and experiences of newer (Z drugs) versus older (benzodiazepine) hypnotics for sleep problems in primary care. Br J Gen Pract 2008;58:417-22
   PubMed Web of Science ®Google Scholar
• Dhanan PS, Mis R. The benzodiazepine problem in primary care: the seriousness and solutions. Qual Prim Care 2005;13:221-4
   Google Scholar
• Ohayon M, Lemoine P. Daytime consequences of insomnia complaints in the French general population. Encephale 2004;30:222-7
   PubMed Web of Science ®Google Scholar
• Riemann D, Fischer J, Mayer G, Peter HJ. The guidelines for ‘non-restorative sleep' relevance for the diagnosis and therapy of insomnia. Somnologie 2003;7:66-76
   Google Scholar
• Charney DS, Minic SJ, Harris RA. editors. Hypnotics and Sedatives. 11th edition. McGraw-Hill, New York 2006
   Google Scholar
• EMA: Guidelines on medicinal products for the treatment of insomnia. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/02/WC500102351.pdf Accessed 2012
   Google Scholar
• Wilson SJ, Nutt DJ, Alford C, British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010;24:1577-601
   PubMed Web of Science ®Google Scholar
• Brzezinski A. Melatonin in humans. N Engl J Med 1997;336:186-95
   PubMed Web of Science ®Google Scholar
• Arendt J, Bojkowski C, Franey C, Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine:abolition of the urinary 24-h rhythm with atenolol. J Clin Endocrinol Metab 1985;60:1166-73
   PubMed Web of Science ®Google Scholar
• Waldhauser F, Waldhauser M, Lieberman HR, Bioavailability of oral melatonin in humans. Neuroendocrinology 1984;39:307-13
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Cutler NL, Sack RL. The endogenous melatonin profile as a marker for circadian phase position. J Biol Rhythms 1999;14:227-36
   PubMed Web of Science ®Google Scholar
• Keijzer H, Smits MG, Peeters T, Evaluation of salivary melatonin measurements for Dim Light Melatonin Onset calculations in patients with possible sleep-wake rhythm disorders. Clin Chim Acta 2011;412:1616-20
   PubMed Web of Science ®Google Scholar
• Sletten TL, Vincenzi S, Redman JR, Timing of sleep and its relationship with the endogenous melatonin rhythm. Front Neurol 2010;1:1
   PubMedGoogle Scholar
• Skene DJ, Arendt J. Circadian rhythm sleep disorders in the blind and their treatment with melatonin. Sleep Med 2007;8:651-5
   PubMed Web of Science ®Google Scholar
• Fares A. Night-time exogenous melatonin administration may be a beneficial treatment for sleeping disorders in beta blocker patients. J Cardiovasc Dis Res 2011;2:153-5
   PubMedGoogle Scholar
• Wyatt JK, Dijk DJ, Ritz-de Cecco A, Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep 2006;29:609-18
   PubMed Web of Science ®Google Scholar
• Cajochen C, Drauchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol 2003;15:432-7
   PubMed Web of Science ®Google Scholar
• Gorfine T, Assaf Y, Goshen-Gottstein Y, Sleep-anticipating effects of melatonin in the human brain. Neuroimage 2006;31:410-18
   PubMed Web of Science ®Google Scholar
• Gorfine T, Zisapel N. Late evening brain activation patterns and their relation to the internal biological time, melatonin, and homeostatic sleep debt. Hum Brain Mapp 2009;30:541-52
   PubMed Web of Science ®Google Scholar
• Rajaratnam SMW, Middleton B, Stone BM, Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities. J Physiol 2004;561:339-51
   PubMed Web of Science ®Google Scholar
• Zisapel N. Circadian rhythm sleep disorders: pathophysiology and potential approaches to management. CNS Drugs 2001;15:311-28
   PubMed Web of Science ®Google Scholar
• Buscemi N, Vandermeer B, Hooton N, The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 2005;20:1151-8
   PubMed Web of Science ®Google Scholar
• Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag 2011;7:577-84
   PubMedGoogle Scholar
• Haimov I, Lavie P, Laudon M, Melatonin replacement therapy of elderly insomniacs. Sleep 1995;18:598-603
   PubMed Web of Science ®Google Scholar
• Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995;346:541-4
   PubMed Web of Science ®Google Scholar
• De Leersnyder H. Inverted rhythm of melatonin secretion in Smith–Magenis syndrome: from symptoms to treatment. Trends Endocrinol Metab 2006;17:291-8
   PubMed Web of Science ®Google Scholar
• Grossman E, Laudon M, Yalcin R, Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med 2006;119:898-902
   PubMed Web of Science ®Google Scholar
• Zisapel N, Tarrasch R, Laudon M. The relationship between melatonin and coritsol rhythms: clinical implications of melatonin therapy. Drug Dev Res 2005;65:119-25
   Web of Science ®Google Scholar
• Pandi-Perumal SR, Trakht I, Srinivasan V, Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 2008;85:335-53
   PubMed Web of Science ®Google Scholar
• Iguchi H, Kato K-I, Ibayashi H. Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 1982;55:27-9
   PubMed Web of Science ®Google Scholar
• Pierpaoli W, Maestroni GJM. Melatonin: a principal neuroimmunoregulatory and anti-stress hormone: its anti-aging effects. Immunol Lett 1987;16:355-61
   PubMed Web of Science ®Google Scholar
• Waldhauser F, Weiszenbacher G, Tatzer E, Alternations in nocturnal serum melatonin levels in humans with growth and aging. J Clin Endocrinol Metab 1988;66:648-52
   PubMed Web of Science ®Google Scholar
• Sharma M, Palacios-Bois J, Schwartz G, Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatr 1989;25:305-19
   PubMed Web of Science ®Google Scholar
• Hofman MA, Swaab DF. Alterations in circadian rhythmicity of the vasopressin-producing neurons of the human suprachiasmatic nucleus (SCN) with aging. Brain Res 1994;651:134-42
   PubMed Web of Science ®Google Scholar
• Czeisler CA, Duffy JF, Shanahan TL, Stability, precision, and near-24-h period of the human circadian pacemaker. Science 1999;284:2177-81
   PubMed Web of Science ®Google Scholar
• Kennaway DJ, Lushington K, Dawson D, Urinary 6-sulfatoxymelatonin excretion and aging: new results and a critical review of the literature. J Pineal Res 1999;27:210-20
   PubMed Web of Science ®Google Scholar
• Mahlberg R, Tilmann A, Salewski L, Kunz D. Normative data on the daily profile of urinary 6-sulfatoxymelatonin in healthy subjects between the ages of 20 and 84. Psychoneuroendocrinology 2006;31:634-41
   PubMed Web of Science ®Google Scholar
• Mahlberg R, Kienast T, Hadel S, Degree of pineal calcification (DOC) is associated with polysomnographic sleep measures in primary insomnia patients. Sleep Med 2009;10:439-45
   PubMed Web of Science ®Google Scholar
• Haimov I, Laudon M, Zisapel N, Sleep disorders and melatonin rhythms in elderly people. BMJ 1994;309:1
   PubMedGoogle Scholar
• Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004;116:91-5
   PubMed Web of Science ®Google Scholar
• Vakkuri O, Leppaluoto J, Kauppila A. Oral administration and distribution of melatonin in human serum, saliva and urine. Life Sci 1985;37:489-95
   PubMed Web of Science ®Google Scholar
• Claustrat B, Le Bars D, Brun J, Plasma and brain pharmacokinetic studies in humans after intraveneous administration of cold or 11 C labelled melatonin. Adv Pineal Res 1989;3:305–10
   Google Scholar
• Le Bars D, Thivolle P, Vitte PA, PET and plasma pharmacokinetic studies after bolus intravenous administration of [11C]melatonin in humans. Int J Rad Appl Instrum B 1991;18:357-62
   PubMedGoogle Scholar
• Aldhous M, Franey C, Wright J, Arendt J. Plasma concentrations of melatonin in man following oral absorption of different preparations. Brit J Clin Pharmacol 1985;19:517-21
   PubMed Web of Science ®Google Scholar
• Shirakawa S, Tsuchiya S, Tsutsumi Y, Time course of saliva and serum melatonin levels after ingestion of melatonin. Psychiatry Clin Neurosci 1998;52:266-7
   PubMed Web of Science ®Google Scholar
• Circadin: European Medicines Agency Public Assessment Reports for Circadin. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/circadin/circadin.htm Accessed 2012
   Google Scholar
• European Medicines Agency. Circadin: Product Information (SPC). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000695/WC500026811.pdf Accessed 2012
   Google Scholar
• Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol 2009;24:239-49
   PubMed Web of Science ®Google Scholar
• Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007;16:372-80
   PubMed Web of Science ®Google Scholar
• Wade A, Zisapel N, Lemoine P. Prolonged-release melatonin for the treatment of Insomnia: targeting quality of sleep and morning alertness. Aging Health 2008;1:11-21
   Google Scholar
• Zisapel N, Laudon M. Subjective assessment of the effects of CNS-active drugs on sleep by the Leeds sleep evaluation questionnaire: a review. Hum Psychopharmacol 2003;18:1-20
   PubMed Web of Science ®Google Scholar
• Hindmarch I. Instrumental assessment of psychomotor functions and the effects of psychotropic drugs. Acta Psychiatr Scand 1994;89(Suppl):49-52
   Google Scholar
• Tarrasch R, Laudon M, Zisapel N. Cross-cultural validation of the Leeds sleep evaluation questionnaire (LSEQ) in insomnia patients. Hum Psychopharmacol 2003;18:603-10
   PubMed Web of Science ®Google Scholar
• Zisapel N, Nir T. Determination of the minimal clinically significant difference on a patient visual analog sleep quality scale. J Sleep Res 2003;12:291-8
   PubMed Web of Science ®Google Scholar
• Backhaus J, Junghanns K, Broocks A, Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J Psychosom Res 2002;53:737-40
   PubMed Web of Science ®Google Scholar
• Wade AG, Ford I, Crawford G, Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007;23:2597-605
   PubMed Web of Science ®Google Scholar
• Bech P, Olsen LR, Kjoller M, Rasmussen NK. Measuring well-being rather than the absence of distress symptoms: a comparison of the SF-36 Mental Health subscale and the WHO-Five Well-Being Scale. Int J Methods Psychiatr Res 2003;12:85-91
   PubMed Web of Science ®Google Scholar
• Wade AG, Ford I, Crawford G, Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med 2010;8:1
   PubMed Web of Science ®Google Scholar
• Wade AG, Ford I, Crawford G, Prolonged release melatonin in the treatment of primary insomnia – evaluation of the age cut-off for short and long-term response. CMRO 2011;27:87-98
   Google Scholar
• Lemoine P, Garfinkel D, Laudon M, Prolonged release melatonin for insomnia – an open label long term study of efficacy, safety and withdrawal symptoms. Ther Clin Risk Manag 2011;7:301-11
   PubMed Web of Science ®Google Scholar
• Garfinkel D, Zorin M, Wainstein J, Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab Syndr Obes 2011;4:307-13
   PubMedGoogle Scholar
• Fairweather DB, Kerr JS, Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol 1992;43:597-601
   PubMed Web of Science ®Google Scholar
• Zolpidem: Clinical Review: FDA: 1992. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019908_S002_AMBIEN_AP.pdf accessed 2012
   Google Scholar
• Ancoli-Israel S. Sleep and aging: prevalence of disturbed sleep and treatment considerations in older adults. J Clin Psychiatry 2005;66(Suppl 9):24-30
   PubMed Web of Science ®Google Scholar
• Ramelteon: Clinical Review: FDA. 2005. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_RozeremTOC.cfm Accessed 2012
   Google Scholar
• Paul MA, Gray G, Sardana TM, Pigeau RA. Melatonin and zopiclone as facilitators of early circadian sleep in operational air transport crews. Aviat Space Environ Med 2004;75:439-43
   PubMed Web of Science ®Google Scholar
• Mets MA, Volkerts ER, Olivier B, Verster JC. Effect of hypnotic drugs on body balance and standing steadiness. Sleep Med Rev 2010;14:259-67
   PubMed Web of Science ®Google Scholar
• Mintzer MZ, Griffiths RR. Selective effects of zolpidem on human memory functions. J Psychopharmacol 1999;13:18-31
   PubMed Web of Science ®Google Scholar
• Rush CR. Behavioral pharmacology of zolpidem relative to benzodiazepines: a review. Pharmacol Biochem Behav 1998;61:253-69
   PubMed Web of Science ®Google Scholar
• Rush CR, Armstrong DL, Ali JA, Pazzaglia PJ. Benzodiazepine-receptor ligands in humans: acute performance-impairing, subject related and observer-rated effects. J Clin Psychopharmacol 1998;18:154-65
   PubMed Web of Science ®Google Scholar
• Brunner D, Dijk D-J, Munch M, Borbely A. Effect of zolpidem on sleep and sleep EEG spectra in healthy young men. Psychopharmacology (Berl) 1991;104:1-5
   PubMed Web of Science ®Google Scholar
• Trachsel L, Dijk DJ, Brunner DP, Effect of zopiclone and midazolam on sleep and EEG spectra in a phase-advanced sleep schedule. Neuropsychopharmacology 1990;3:11-18
   PubMed Web of Science ®Google Scholar
• Borbely A. Processes underlying sleep regulation. Horm Res 1998;49:114-17
   PubMed Web of Science ®Google Scholar
• Otmani S, Demazieres A, Staner C, Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol 2008;23:693-705
   PubMed Web of Science ®Google Scholar
• Millet B, Bayle FJ, Olie JP. Prospects for anxiolytic therapy: a reflection from different viewpoints. Drug Discov Today 1998;3:471-9
   Web of Science ®Google Scholar
• Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328:1398-405
   PubMed Web of Science ®Google Scholar
• Lu B, Budhiraja R, Parthasarathy S. Sedating medications and undiagnosed obstructive sleep apnea: physician determinants and patient consequences. J Clin Sleep Med 2005;1:367-71
   PubMed Web of Science ®Google Scholar
• Rachmani R, Shenhav G, Slavachevsky I, Use of a mild sedative helps to identify true non-dippers by ABPM: a study in patients with diabetes mellitus and hypertension. Blood Press Monit 2004;9:65-9
   PubMed Web of Science ®Google Scholar
• Arbon E, Knoriwska M, Dijk DJ. Comparing the effects of prolonged release melatonin, temazepam and zolpidem on EEG power spectra during nocturnal sleep in healthy middle aged men and women. J Sleep Res 2010;19(Suppl 2):1
   Google Scholar
• Zisapel N. Controlled release melatonin (Circadin) in the treatment of insomnia in older patients: efficacy and safety in patients with history of use and non-use of hypnotic drugs. Harefuah 2009;148:337-341;
   PubMedGoogle Scholar
• Garfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch Intern Med 1999;159:2456-60
   PubMed Web of Science ®Google Scholar
• Dagan Y, Zisapel N, Nof D, Rapid reversal of tolerance to benzodiazepine hypnotics by treatment with oral melatonin: a case report. Eur Neuropsychopharmacol 1997;7:2157-60
   Web of Science ®Google Scholar
• Kunz D, Bineau S, Maman K, Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database. Expert Opin Pharmacother 2012;13(1):9-16
   PubMed Web of Science ®Google Scholar
• Monane M. Insomnia in the elderly. J Clin Psychiatry 1992;53(Suppl):23-8
   PubMed Web of Science ®Google Scholar